Replicative homeostasis III: Implications for antiviral therapy and mechanisms of response and non-response

Virology Journal

Volumn 4, Issue , 2007, Pages

  Sallie, Richard ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MUTAGENIC AGENT; MYCOPHENOLIC ACID; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POL PROTEIN; RIBAVIRIN; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED RNA POLYMERASE; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VX 492;

ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONSENSUS SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; GENOTYPE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; MATHEMATICAL MODEL; MONOTHERAPY; PROTEIN PROTEIN INTERACTION; RNA REPLICATION; RNA VIRUS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; ADAPTATION; GENETIC VARIABILITY; GENETICS; HEPATITIS C VIRUS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADAPTATION, BIOLOGICAL; DRUG SYNERGISM; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; TREATMENT OUTCOME; VARIATION (GENETICS); VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 34047225254     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-29     Document Type: Article

References (151)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. MJ Alter D Kruszon-Moran OV Nainan GM McQuillan F Gao LA Moyer RA Kaslow HS Margolis, N Engl J Med 1999 341 8 556 562 10.1056/NEJM199908193410802 10451460
2. Projecting the future healthcare burden from hepatitis C in the United States (abstract). GL Davis JE Albright SF Cook DM Rosenberg, Hepatology 1998 28 Suppl 4, pt 2 99A
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr. D Haussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu, N Engl J Med 2002 347 13 975 982 10.1056/NEJMoa020047 12324553
4. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. JG McHutchison JA Shad SC Gordon TR Morgan MH Ling JJ Garaud JK Albrecht JL Dienstag, J Viral Hepat 2001 8 6 414 420 10.1046/j.1365-2893.2001.00312.x 11703572
5. Molecular virology and the development of resistant mutants: implications for therapy. S Locarnini, Semin Liver Dis 2005 25 Suppl 1 9 19 10.1055/s-2005-915645 16103977
6. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. R McKenzie MW Fried R Sallie H Conjeevaram AM Di Bisceglie Y Park B Savarese D Kleiner M Tsokos C Luciano, N Engl J Med 1995 333 17 1099 1105 10.1056/NEJM199510263331702 7565947
7. Duration of HCV infection as a predictor of nonresponse to interferon. A Craxi V Di Marco C Camma P Almasio S Magrin, Dig Dis Sci 1996 41 12 Suppl 86S 92S 10.1007/BF02087881 9011482
8. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. HS Conjeevaram MW Fried LJ Jeffers NA Terrault TE Wiley-Lucas N Afdhal RS Brown SH Belle JH Hoofnagle DE Kleiner CD Howell, Gastroenterology 2006 131 2 470 477 10.1053/j.gastro.2006.06. 008 16890601
9. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. G Tarantino P Conca P Sorrentino M Ariello, J Gastroenterol Hepatol 2006 21 8 1266 1268 10.1111/j.1440-1746.2006. 04394.x 16872307
10. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. RP Woitas M Lechmann G Jung R Kaiser T Sauerbruch U Spengler, J Immunol 1997 159 2 1012 1018 9218624
11. Analysis of successful immune responses in persons infected with hepatitis C virus. F Lechner DK Wong PR Dunbar R Chapman RT Chung P Dohrenwend G Robbins R Phillips P Klenerman BD Walker, J Exp Med 2000 191 9 1499 1512 10.1084/jem.191.9.1499 10790425
12. Immune-based novel therapies for chronic hepatitis C virus infection. K Kakimi, Hum Cell 2003 16 4 191 197 15147039
13. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. W Li DK Krishnadas J Li DL Tyrrell B Agrawal, J Immunol 2006 176 10 6065 6075 16670315
14. Adaptation of wild-type measles virus to CD46 receptor usage. L Nielsen M Blixenkrone-Moller M Thylstrup NJ Hansen G Bolt, Arch Virol 2001 146 2 197 208 10.1007/s007050170169 11315632
15. Replicative Homeostasis II: Influence of polymerase fidelity on RNA virus quasispecies biology: Implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. R Sallie, Virol J 2005 2 1 70 16115320 10.1186/1743-422X-2-70
16. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. M Gale Jr. B Kwieciszewski M Dossett H Nakao MG Katze, J Virol 1999 73 8 6506 6516 10400746
17. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. K Li E Foy JC Ferreon M Nakamura AC Ferreon M Ikeda SC Ray M Gale Jr. SM Lemon, Proc Natl Acad Sci U S A 2005 102 8 2992 2997 15710891 10.1073/pnas.0408824102
18. Effects of the hepatitis C virus core protein on innate cellular defense pathways. K Miller S McArdle MJ Gale Jr. DA Geller B Tenoever J Hiscott DR Gretch SJ Polyak, J Interferon Cytokine Res 2004 24 7 391 402 10.1089/1079990041535647 15296650
19. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. SJ Polyak DM Paschal S McArdle MJ Gale Jr. D Moradpour DR Gretch, Hepatology 1999 29 4 1262 1271 10.1002/hep.510290438 10094974
20. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. E Foy K Li R Sumpter Jr. YM Loo CL Johnson C Wang PM Fish M Yoneyama T Fujita SM Lemon M Gale Jr., Proc Natl Acad Sci U S A 2005 102 8 2986 2991 15710892 10.1073/pnas.0408707102
21. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. E Foy K Li C Wang R Sumpter Jr. M Ikeda SM Lemon M Gale Jr., Science 2003 300 5622 1145 1148 10.1126/science.1082604 12702807
22. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. F Martin C Volpari C Steinkuhler N Dimasi M Brunetti G Biasiol S Altamura R Cortese R De Francesco M Sollazzo, Protein Eng 1997 10 5 607 614 10.1093/protein/10.5.607 9215580
23. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. C Trozzi L Bartholomew A Ceccacci G Biasiol L Pacini S Altamura F Narjes E Muraglia G Paonessa U Koch R De Francesco C Steinkuhler G Migliaccio, J Virol 2003 77 6 3669 3679 12610142 10.1128/JVI.77.6.3669-3679.2003
24. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. RB Perni SJ Almquist RA Byrn G Chandorkar PR Chaturvedi LF Courtney CJ Decker K Dinehart CA Gates SL Harbeson A Heiser G Kalkeri E Kolaczkowski K Lin YP Luong BG Rao WP Taylor JA Thomson RD Tung Y Wei AD Kwong C Lin, Antimicrob Agents Chemother 2006 50 3 899 909 16495249 10.1128/AAC.50.3.899-909.2006
25. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. VG Bain KD Kaita EM Yoshida MG Swain EJ Heathcote AU Neumann M Fiscella R Yu BL Osborn PW Cronin WW Freimuth JG McHutchison GM Subramanian, J Hepatol 2006 44 4 671 678 10.1016/j.jhep.2005.12. 011 16487617
26. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. JJ Feld JH Hoofnagle, Nature 2005 436 7053 967 972 10.1038/nature04082 16107837
27. Replicative Homeostasis: A fundamental mechanism mediating selective viral replication and escape mutation. R Sallie, Virol J 2005 2 1 10 15707489 10.1186/1743-422X-2-10
28. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. A Tsubota K Chayama Y Arase I Koida S Saitoh K Ikeda S Iwasaki T Matsumoto M Kobayashi H Kumada, J Gastroenterol Hepatol 1993 8 6 535 539 7506584
29. Alpha interferon treatment in chronic hepatitis C. G Ideo A Bellobuono L Mondazzi S Tempini G Bellati GM Ideo E Silini, Clin Exp Rheumatol 1995 13 Suppl 13 S167 73 8730501
30. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C. M Mizokami E Orito Y Gibo K Suzuki K Ohba T Ohno JY Lau, Liver 1996 16 1 23 27 8868074
31. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. M Martinot-Peignoux P Marcellin M Pouteau C Castelnau N Boyer M Poliquin C Degott I Descombes V Le Breton V Milotova, Hepatology 1995 22 4 Pt 1 1050 1056 10.1002/hep.1840220406 7557850
32. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. K Hino S Sainokami K Shimoda S Iino Y Wang H Okamoto Y Miyakawa M Mayumi, J Med Virol 1994 42 3 299 305 10.1002/jmv.1890420318 7516422
33. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. A Mangia R Santoro N Minerva GL Ricci V Carretta M Persico F Vinelli G Scotto D Bacca M Annese M Romano F Zechini F Sogari F Spirito A Andriulli, N Engl J Med 2005 352 25 2609 2617 10.1056/NEJMoa042608 15972867
34. Genotypic analysis of hepatitis C virus in American patients. K Mahaney V Tedeschi G Maertens AM Di Bisceglie J Vergalla JH Hoofnagle R Sallie, Hepatology 1994 20 6 1405 1411 10.1002/hep.1840200605 7982639
35. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. P Ferenci E Formann H Laferl M Gschwantler F Hackl H Brunner R Hubmann C Datz R Stauber P Steindl-Munda HH Kessler A Klingler A Gangl, J Hepatol 2006 44 2 275 282 10.1016/j.jhep.2005.09.015 16338019
36. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. ML Yu WL Chuang CY Dai LP Lee MY Hsieh ZY Lin SC Chen MY Hsieh LY Wang WY Chang SL Tsai HT Kuo, Transl Res 2006 148 3 120 127 10.1016/j.trsl.2006.04.006 16938649
37. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. N Furusyo M Katoh Y Tanabe E Kajiwara T Maruyama J Shimono H Sakai M Nakamuta H Nomura A Masumoto S Shimoda K Takahashi K Azuma J Hayashi, World J Gastroenterol 2006 12 5 784 790 16521196
38. [Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)]. J Juszczyk B Baka-Cwierz M Beniowski H Berak B Bolewska A Boron-Kaczmarska J Cianciara A Ciesla A Dziambor J Gasiorowski A Gietka E Gliwinska A Gladysz Z Gonciarz W Halota A Horban M Inglot U Janas-Skulina E Janczewska-Kazek J Jaskowska K Jurczyk B Knysz W Kryczka J Kuydowicz EA Lakomy B Logiewa-Bazger A Lyczak T Mach W Mazur Z Michalska R Modrzewska K Nazzal P Pabjan A Piekarska P Piszko K Sikorska K Szamotulska M Sliwinska K Swietek K Tomasiewicz E Topczewska-Staubach H Trocha M Wasilewski M Wawrzynowicz-Syczewska W Wrodycki D Zarebska-Michaluk M Zejc-Bajsarowicz, Przegl Epidemiol 2005 59 3 651 660 16433307
39. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. M von Wagner M Huber T Berg H Hinrichsen J Rasenack T Heintges A Bergk C Bernsmeier D Haussinger E Herrmann S Zeuzem, Gastroenterology 2005 129 2 522 527 10.1016/j.gastro.2005.05.008 16083709
40. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. SM Kamal AA El Tawil T Nakano Q He J Rasenack SA Hakam WA Saleh A Ismail AA Aziz MA Madwar, Gut 2005 54 6 858 866 10.1136/gut.2004.057182 15888797
41. Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. S Gaudieri A Rauch LP Park E Freitas S Herrmann G Jeffrey W Cheng K Pfafferott K Naidoo R Chapman M Battegay R Weber A Telenti H Furrer I James M Lucas SA Mallal, J Virol 2006 80 22 11094 11104 17071929 10.1128/JVI.00912-06
42. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. N Paladino H Fainboim G Theiler T Schroder AE Munoz AC Flores O Galdame L Fainboim, J Virol 2006 80 18 9144 9150 16940525 10.1128/JVI.00339-06
43. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. HC Spangenberg S Viazov N Kersting C Neumann-Haefelin D McKinney M Roggendorf F von Weizsacker HE Blum R Thimme, Hepatology 2005 42 4 828 837 10.1002/hep.20856 16175596
44. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). SS Lee EJ Heathcote KR Reddy S Zeuzem MW Fried TL Wright PJ Pockros D Haussinger CI Smith A Lin SC Pappas, J Hepatol 2002 37 4 500 506 10.1016/S0168-8278(02)00211-8 12217604
45. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. N Akuta F Suzuki H Sezaki Y Suzuki T Hosaka T Someya M Kobayashi S Saitoh S Watahiki J Sato M Kobayashi Y Arase K Ikeda H Kumada, J Med Virol 2006 78 1 83 90 10.1002/jmv.20507 16299715
46. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. N Yuki N Hayashi A Kasahara H Hagiwara T Takehara M Oshita K Katayama H Fusamoto T Kamada, J Hepatol 1995 22 4 457 463 10.1016/0168-8278(95)80109-X 7665863
47. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. F Puig-Basagoiti X Forns I Furcic S Ampurdanes M Gimenez-Barcons S Franco JM Sanchez-Tapias JC Saiz, J Gen Virol 2005 86 Pt 4 1067 1075 10.1099/vir.0.80526-0 15784900
48. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. C Morishima SJ Polyak R Ray MC Doherty AM Di Bisceglie PF Malet HL Bonkovsky DG Sullivan DR Gretch AL Rothman MJ Koziel KL Lindsay, J Infect Dis 2006 193 7 931 940 10.1086/500952 16518754
49. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. AR Zekri HM Alam El-Din AA Bahnassy MM Khaled A Omar I Fouad M El-Hefnewi F Thakeb M El-Awady, Virol J 2007 4 1 16 17300723 10.1186/1743-422X-4-16
50. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. CT Wai CJ Chu M Hussain AS Lok, Hepatology 2002 36 6 1425 1430 12447868
51. The origin of genetic information. M Eigen W Gardiner P Schuster R Winkler-Oswatitsch, Sci Am 1981 244 4 88 92, 96, et passim 6164094
52. The hypercycle. Coupling of RNA and protein biosynthesis in the infection cycle of an RNA bacteriophage. M Eigen CK Biebricher M Gebinoga WC Gardiner, Biochemistry 1991 30 46 11005 11018 10.1021/bi00110a001 1932025
53. The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. M Eigen P Schuster, Naturwissenschaften 1977 64 11 541 565 10.1007/BF00450633 593400
54. Origin of life between Scylla and Charybdis. U Niesert D Harnasch C Bresch, J Mol Evol 1981 17 6 348 353 10.1007/BF01734356 7288889
55. 30 years later - a new approach to Sol Spiegelman's and Leslie Orgel's in vitro evolutionary studies. Dedicated to Leslie Orgel on the occasion of his 70th birthday. F Oehlenschlager M Eigen, Orig Life Evol Biosph 1997 27 5-6 437 457 10.1023/A:1006501326129 9394469
56. The paradox of HIV nef function: resolution of the contradictions. R Sallie, Med Hypotheses 2005 65 1 44 46 10.1016/j.mehy.2005.02.008 15893116
57. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. J Bukh RH Miller RH Purcell, Semin Liver Dis 1995 15 1 41 63 7597443
58. Evolution of the hypervariable region of hepatitis C virus. DB Smith, J Viral Hepat 1999 6 Suppl 1 41 46 10.1046/j.1365-2893.1999.00010.x 10760034
59. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J McAllister C Casino F Davidson J Power E Lawlor PL Yap P Simmonds DB Smith, J Virol 1998 72 6 4893 4905 9573256
60. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. G Puntoriero A Meola A Lahm S Zucchelli BB Ercole R Tafi M Pezzanera MU Mondelli R Cortese A Tramontano G Galfre A Nicosia, Embo J 1998 17 13 3521 3533 9649423 10.1093/emboj/17.13.3521
61. Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior. A Marrone R Sallie, Clin Lab Med 1996 16 2 429 449 8792081
62. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. D Herion JH Hoofnagle, Hepatology 1997 25 3 769 771 10.1002/hep.510250346 9049233
63. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Enomoto I Sakuma Y Asahina M Kurosaki T Murakami C Yamamoto Y Ogura N Izumi F Marumo C Sato, N Engl J Med 1996 334 2 77 81 10.1056/NEJM199601113340203 8531962
64. Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A. K Watanabe K Yoshioka M Yano M Ishigami K Ukai H Ito F Miyata T Mizutani H Goto, J Med Virol 2005 75 4 504 512 10.1002/jmv.20301 15714488
65. Variations within hepatitis C virus E2 protein and response to interferon treatment. S Lo HH Lin, Virus Res 2001 75 2 107 112 10.1016/S0168-1702(01) 00224-6 11325465
66. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. SE Bassett B Guerra K Brasky E Miskovsky M Houghton GR Klimpel RE Lanford, Hepatology 2001 33 6 1479 1487 10.1053/jhep.2001.24371 11391537
67. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. AM Prince B Brotman DH Lee L Ren BS Moore JW Scheffel, J Infect Dis 1999 180 4 987 991 10.1086/314973 10479122
68. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. A Sakai MS Claire K Faulk S Govindarajan SU Emerson RH Purcell J Bukh, Proc Natl Acad Sci U S A 2003 100 20 11646 11651 14504405 10.1073/pnas.1834545100
69. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. E Meurs K Chong J Galabru NS Thomas IM Kerr BR Williams AG Hovanessian, Cell 1990 62 2 379 390 10.1016/0092-8674(90)90374-N 1695551
70. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. MJ Gale Jr. MJ Korth NM Tang SL Tan DA Hopkins TE Dever SJ Polyak DR Gretch MG Katze, Virology 1997 230 2 217 227 10.1006/viro.1997.8493 9143277
71. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. DR Taylor ST Shi PR Romano GN Barber MM Lai, Science 1999 285 5424 107 110 10.1126/science.285.5424.107 10390359
72. Replication protein A as a "fidelity clamp" for DNA polymerase alpha. G Maga I Frouin S Spadari U Hubscher, J Biol Chem 2001 276 21 18235 18242 10.1074/jbc.M009599200 11278525
73. Fidelity of RNA polymerase II transcription controlled by elongation factor TFIIS. C Jeon K Agarwal, Proc Natl Acad Sci U S A 1996 93 24 13677 13682 8942993 10.1073/pnas.93.24.13677
74. Human telomerase and its regulation. YS Cong WE Wright JW Shay, Microbiol Mol Biol Rev 2002 66 3 407 25, table of contents 12208997 10.1128/MMBR.66.3. 407-425.2002
75. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. IM Jacobson SA Gonzalez F Ahmed E Lebovics AD Min HC Bodenheimer Jr. SP Esposito RS Brown Jr. N Brau FM Klion H Tobias EJ Bini N Brodsky MA Cerulli A Aytaman PW Gardner JM Geders JE Spivack MG Rahmin DH Berman J Ehrlich MW Russo M Chait D Rovner BR Edlin, Am J Gastroenterol 2005 100 11 2453 2462 10.1111/j.1572-0241.2005.00282.x 16279900
76. Mutations in interferon sensitivity-determining region of hepatitis C virus: its relation to change in viral load. Y Terazawa K Yoshioka M Kobayashi K Watanabe M Ishigami M Yano K Takagi S Kakumu, Am J Gastroenterol 2000 95 7 1781 1787 10925985
77. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. M Kobayashi K Watanabe M Ishigami K Murase H Ito K Ukai M Yano K Takagi M Hattori S Kakumu K Yoshioka, Am J Gastroenterol 2002 97 4 988 998 10.1111/j.1572-0241.2002.05619.x 12003437
78. Antiviral action of ribavirin in chronic hepatitis C. JM Pawlotsky H Dahari AU Neumann C Hezode G Germanidis I Lonjon L Castera D Dhumeaux, Gastroenterology 2004 126 3 703 714 10.1053/j.gastro.2003.12.002 14988824
79. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. FC Bekkering JT Brouwer BE Hansen SW Schalm, J Hepatol 2001 34 3 435 440 10.1016/S0168-8278(00)00033-7 11322206
80. HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. F Mustafa JF Richmond R Fernandez-Larsson S Lu R Fredriksson EM Fenyo M O'Connell E Johnson J Weng JC Santoro HL Robinson, Virology 1997 229 1 269 278 10.1006/viro.1997.8445 9123870
81. Identification of HIV-1 determinants for replication in vivo. L Su H Kaneshima ML Bonyhadi R Lee J Auten A Wolf B Du L Rabin BH Hahn E Terwilliger JM McCune, Virology 1997 227 1 45 52 10.1006/viro.1996.8338 9007057
82. The Semliki Forest virus E2 gene as a virulence determinant. MG Santagati JA Maatta PV Itaranta AA Salmi AE Hinkkanen, J Gen Virol 1995 76 ( Pt 1) 47 52 7844541
83. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. J Torresi L Earnest-Silveira G Civitico TE Walters SR Lewin J Fyfe SA Locarnini M Manns C Trautwein TC Bock, Virology 2002 299 1 88 99 10.1006/viro.2002.1448 12167344
84. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. A Berger M von Depka Prondzinski HW Doerr H Rabenau B Weber, J Med Virol 1996 48 4 339 343 10.1002/(SICI)1096-9071(199604)48:4<339: :AID-JMV7>3.0.CO;2-8 8699166
85. Relationship between viral genotype and viral load in patients with chronic hepatitis C. F Garcia C Roldan J Hernandez-Quero MC Bernal MA Martinez MA Lopez G Piedrola MC Maroto, Eur J Clin Microbiol Infect Dis 1996 15 11 884 887 10.1007/BF01691224 8997565
86. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. L De Moliner P Pontisso GL De Salvo L Cavalletto L Chemello A Alberti, Gut 1998 42 6 856 860 9691926
87. Treatment of acute hepatitis C with interferon alfa-2b. E Jaeckel M Cornberg H Wedemeyer T Santantonio J Mayer M Zankel G Pastore M Dietrich C Trautwein MP Manns, N Engl J Med 2001 345 20 1452 1457 10.1056/NEJMoa011232 11794193
88. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. J Wiegand P Buggisch W Boecher S Zeuzem CM Gelbmann T Berg W Kauffmann B Kallinowski M Cornberg E Jaeckel H Wedemeyer MP Manns, Hepatology 2006 43 2 250 256 10.1002/hep.21043 16440367
89. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. T Santantonio M Fasano E Sinisi A Guastadisegni C Casalino M Mazzola R Francavilla G Pastore, J Hepatol 2005 42 3 329 333 10.1016/j.jhep.2004.11.021 15710214
90. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. R Sumpter Jr. YM Loo E Foy K Li M Yoneyama T Fujita SM Lemon M Gale Jr., J Virol 2005 79 5 2689 2699 15708988 10.1128/JVI.79.5.2689-2699.2005
91. Evasion of intracellular host defence by hepatitis C virus. M Gale Jr. EM Foy, Nature 2005 436 7053 939 945 10.1038/nature04078 16107833
92. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. MJ Gale Jr. MJ Korth MG Katze, Clin Diagn Virol 1998 10 2-3 157 162 10.1016/S0928-0197(98)00034-8 9741641
93. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. M Gale Jr. MG Katze, Pharmacol Ther 1998 78 1 29 46 10.1016/S0163-7258(97)00165-4 9593328
94. Kinetics of the immune response during HBV and HCV infection. A Bertoletti C Ferrari, Hepatology 2003 38 1 4 13 10.1053/jhep.2003.50310 12829979
95. The kinetics of hepatitis C virus infection. S Zeuzem, Clin Liver Dis 2001 5 4 917 930 10.1016/S1089-3261(05)70201-4 11685801
96. Functional classification of interferon-stimulated genes identified using microarrays. MJ de Veer M Holko M Frevel E Walker S Der JM Paranjape RH Silverman BR Williams, J Leukoc Biol 2001 69 6 912 920 11404376
97. Effector genes of interferon action against hepatitis C virus. M Gale Jr., Hepatology 2003 37 5 975 978 10.1053/jhep.2003.50201 12717377
98. Signal transduction and activation of gene transcription by interferons. KC Gilmour NC Reich, Gene Expr 1995 5 1 1 18 7488857
99. Human interferons alpha, beta and omega. J Bekisz H Schmeisser J Hernandez ND Goldman KC Zoon, Growth Factors 2004 22 4 243 251 10.1080/08977190400000833 15621727
100. Viruses and interferons. GC Sen, Annu Rev Microbiol 2001 55 255 281 10.1146/annurev.micro.55.1.255 11544356
101. Interferon-mediated antiviral state in human MRC5 cells in the absence of detectable levels of 2-5A synthetase and protein kinase. E Meurs AG Hovanessian L Montagnier, J Interferon Res 1981 1 2 219 232 6180053
102. Mechanism of the interferon alpha response against hepatitis C virus replicons. JT Guo JA Sohn Q Zhu C Seeger, Virology 2004 325 1 71 81 10.1016/j.virol.2004.04.031 15231387
103. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. BK Biswal MM Cherney M Wang L Chan CG Yannopoulos D Bilimoria O Nicolas J Bedard MN James, J Biol Chem 2005 280 18 18202 18210 10.1074/jbc.M413410200 15746101
104. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. RT Chung W He A Saquib AM Contreras RJ Xavier A Chawla TC Wang EV Schmidt, Proc Natl Acad Sci U S A 2001 98 17 9847 9852 11493707 10.1073/pnas.171319698
105. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. S Crotty D Maag JJ Arnold W Zhong JY Lau Z Hong R Andino CE Cameron, Nat Med 2000 6 12 1375 1379 10.1038/82191 11100123
106. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. D Maag C Castro Z Hong CE Cameron, J Biol Chem 2001 276 49 46094 46098 10.1074/jbc.C100349200 11602568
107. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. RC Tam B Pai J Bard C Lim DR Averett UT Phan T Milovanovic, J Hepatol 1999 30 3 376 382 10.1016/S0168-8278(99)80093-2 10190717
108. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. JY Lau RC Tam TJ Liang Z Hong, Hepatology 2002 35 5 1002 1009 10.1053/jhep.2002.32672 11981750
109. RNA virus error catastrophe: direct molecular test by using ribavirin. S Crotty CE Cameron R Andino, Proc Natl Acad Sci U S A 2001 98 12 6895 6900 11371613 10.1073/pnas.111085598
110. Mechanisms of action of ribavirin against distinct viruses. JD Graci CE Cameron, Rev Med Virol 2006 16 1 37 48 10.1002/rmv.483 16287208
111. Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. KW Pankiewicz K Lesiak-Watanabe KA Watanabe K Malinowski, Curr Med Chem 1999 6 7 629 634 10390605
112. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. SD Henry HJ Metselaar RC Lonsdale A Kok BL Haagmans HW Tilanus LJ van der Laan, Gastroenterology 2006 131 5 1452 1462 10.1053/j.gastro.2006.08.027 17101321
113. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. SK Wray BE Gilbert MW Noall V Knight, Antiviral Res 1985 5 1 29 37 10.1016/0166-3542(85)90012-9 3985606
114. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. NV Vo KC Young MM Lai, Biochemistry 2003 42 35 10462 10471 10.1021/bi0344681 12950173
115. Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. I Bougie M Bisaillon, J Biol Chem 2003 278 52 52471 52478 10.1074/jbc.M308917200 14563844
116. The clinical pharmacology of ribavirin. P Glue, Semin Liver Dis 1999 19 Suppl 1 17 24 10349689
117. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden AS Perelson, Science 1998 282 5386 103 107 10.1126/science.282.5386.103 9756471
118. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. E Herrmann JH Lee G Marinos M Modi S Zeuzem, Hepatology 2003 37 6 1351 1358 10.1053/jhep.2003.50218 12774014
119. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. NM Dixit JE Layden-Almer TJ Layden AS Perelson, Nature 2004 432 7019 922 924 10.1038/nature03153 15602565
120. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. JE Layden-Almer RM Ribeiro T Wiley AS Perelson TJ Layden, Hepatology 2003 37 6 1343 1350 10.1053/jhep.2003. 50217 12774013
121. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo V Bain J Heathcote S Zeuzem C Trepo J Albrecht, Lancet 1998 352 9138 1426 1432 10.1016/S0140-6736(98)07124-4 9807989
122. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 358 9286 958 965 10.1016/S0140-6736(01) 06102-5 11583749
123. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. AU Neumann NP Lam H Dahari M Davidian TE Wiley BP Mika AS Perelson TJ Layden, J Infect Dis 2000 182 1 28 35 10.1086/315661 10882578
124. Hepatitis C virus kinetics. E Herrmann AU Neumann JM Schmidt S Zeuzem, Antivir Ther 2000 5 2 85 90 10971860
125. New kinetic models for the hepatitis C virus. AS Perelson E Herrmann F Micol S Zeuzem, Hepatology 2005 42 4 749 754 10.1002/hep.20882 16175615
126. Self-replication with errors. A model for polynucleotide replication. J Swetina P Schuster, Biophys Chem 1982 16 4 329 345 10.1016/0301-4622(82)87037-3 7159681
127. Examining the theory of error catastrophe. J Summers S Litwin, J Virol 2006 80 1 20 26 16352527 10.1128/JVI.80.1.20-26.2006
128. The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. R Sanjuan A Moya SF Elena, Proc Natl Acad Sci U S A 2004 101 22 8396 8401 15159545 10.1073/pnas.0400146101
129. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. J Brok LL Gluud C Gluud, Am J Gastroenterol 2006 101 4 842 847 10.1111/j.1572-0241.2006.00505.x 16494584
130. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. KC Young KL Lindsay KJ Lee WC Liu JW He SL Milstein MM Lai, Hepatology 2003 38 4 869 878 14512874
131. Preextinction viral RNA can interfere with infectivity. C Gonzalez-Lopez A Arias N Pariente G Gomez-Mariano E Domingo, J Virol 2004 78 7 3319 3324 15016853 10.1128/JVI.78.7.3319-3324.2004
132. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. A Grande-Perez S Sierra MG Castro E Domingo PR Lowenstein, Proc Natl Acad Sci U S A 2002 99 20 12938 12943 12215495 10.1073/pnas.182426999
133. Optimal therapy of hepatitis C. AM Di Bisceglie JH Hoofnagle, Hepatology 2002 36 5 Suppl 1 S121 7 10.1002/hep.1840360716 12407585
134. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi ZD Goodman MH Ling S Cort JK Albrecht, N Engl J Med 1998 339 21 1485 1492 10.1056/ NEJM199811193392101 9819446
135. Prolonged therapy of chronic hepatitis C with ribavirin. JH Hoofnagle D Lau H Conjeevaram D Kleiner AM Di Bisceglie, J Viral Hepat 1996 3 5 247 252 8914004
136. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. AM Di Bisceglie HS Conjeevaram MW Fried R Sallie Y Park C Yurdaydin M Swain DE Kleiner K Mahaney JH Hoofnagle, Ann Intern Med 1995 123 12 897 903 7486483
137. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. F Zoulim J Haem SS Ahmed P Chossegros F Habersetzer M Chevallier F Bailly C Trepo, J Viral Hepat 1998 5 3 193 198 10.1046/j.1365-2893.1998.00099.x 9658373
138. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. G Dusheiko J Main H Thomas O Reichard C Lee A Dhillon S Rassam A Fryden H Reesink M Bassendine G Norkrans T Cuypers N Lelie P Telfer J Watson C Weegink P Sillikens O Weiland, J Hepatol 1996 25 5 591 598 10.1016/S0168-8278(96)80225-X 8938532
139. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. C Hultgren DR Milich O Weiland M Sallberg, J Gen Virol 1998 79 ( Pt 10) 2381 2391 9780043
140. Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. K Ishii Y Sumino M Shinohara K Higami K Matsumaru Y Fujita K Sasao N Wakui M Shinohara H Nagai M Watanabe K Miki, Hepatol Res 2006 34 1 15 22 10.1016/j.hepres.2005.09.039 16293442
141. Uniquely altered DNA replication fidelity conferred by an amino acid change in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase. DA Lewis K Bebenek WA Beard SH Wilson TA Kunkel, J Biol Chem 1999 274 46 32924 32930 10.1074/jbc.274.46.32924 10551858
142. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. JK Pfeiffer K Kirkegaard, Proc Natl Acad Sci U S A 2003 100 12 7289 7294 12754380 10.1073/pnas.1232294100
143. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. C Pichoud F Berby L Stuyver MA Petit C Trepo F Zoulim, J Hepatol 2000 32 2 307 316 10.1016/S0168-8278(00)80077-X 10707872
144. [Persistence of hepatitis B virus in children after interferon-alpha therapy despite the seroconversion in HBsAg/anti-HBs system]. H Gregorek K Dzierzanowska-Fangrat M Woynarowski P Jozwiak E Witkowska-Vogtt U Wojda M Syczewska J Socha K Madaliniski, Przegl Epidemiol 2005 59 3 641 649 16433306
145. Interferon-alpha and autoimmune thyroid disease. MF Prummel P Laurberg, Thyroid 2003 13 6 547 551 10.1089/105072503322238809 12930598
146. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. KC Conlon WJ Urba JW Smith 2nd RG Steis DL Longo JW Clark, Cancer 1990 65 10 2237 2242 10.1002/1097-0142(19900515)65:10<2237:: AID-CNCR2820651013>3.0.CO;2-5 2346907
147. Immunotherapy of chronic hepatitis B by anti HBV vaccine. S Pol, Biomed Pharmacother 1995 49 3 105 109 10.1016/0753-3322(96)82602-3 7647280
148. A case-control study of serious autoimmune adverse events following hepatitis B immunization. DA Geier MR Geier, Autoimmunity 2005 38 4 295 301 10.1080/08916930500144484 16206512
149. Dose response study of an inactivated hepatitis A virus vaccine. RM Carlsson BA Claesson SA Iwarson, J Hepatol 1993 18 Suppl 2 S41 5 10.1016/S0168-8278(05)80377-0 8182272
150. Multicentre dose range study of a yeast-derived hepatitis B vaccine. G Wiedermann N Scheiermann P Goubau F Ambrosch M Gesemann C De Bel P Kremsner D Paar C Kunz P Hauser, Vaccine 1987 5 3 179 183 10.1016/0264-410X(87)90096-X 3673204
151. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. M Gale Jr. CM Blakely B Kwieciszewski SL Tan M Dossett NM Tang MJ Korth SJ Polyak DR Gretch MG Katze, Mol Cell Biol 1998 18 9 5208 5218 9710605